Standard UK Delivery from £2.49

Please enable cookies to use this site. Why?

Kelapril

Kelapril Tablets are for the treatment of congestive heart failure in dogs, and for the reduction of proteinuria associated with chronic kidney disease in cats. They should be given once daily with or without food and can be used with an unlimited duration.

Kelapril Tablets oval shaped tablets that are either light yellow or reddish pink in colour. They are scored on both sides for easy and accurate dosing.

Loading...
Kelapril 20mg Tablets for Dogs

Kelapril 20mg Tablets for Dogs

£2.23

Kelapril 20mg Tablets are indicated for the treatment of congestive heart failure in dogs. Kelapril Tablets should be given orally once daily with or without food. Each Tablet Contains: ...[More info]

£2.23
Kelapril 5mg Tablets for Dogs and Cats

Kelapril 5mg Tablets for Dogs and Cats

£1.09

Kelapril 5mg Tablets are indicated for the treatment of congestive heart failure in dogs, and for the reduction of proteinuria associated with chronic kidney disease in cats. Kelapril...[More info]

£1.09

Contraindications
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.
Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.
Do not use in pregnancy or lactation

Special warnings for each target species
None.

Special precautions for use in animals
No evidence of renal toxicity of the veterinary medicinal product has been observed (in dogs or cats) during clinical trials, however, as is routine in cases of chronic kidney disease, it is recommended to monitor plasma creatinine, urea and erythrocyte counts during therapy.
The efficacy and safety of the product has not been established in dogs and cats below 2.5 kg body weight.

Special precautions to be taken by the person administering the veterinary medicinal product to animals
Wash hands after use.
To avoid accidental ingestion, particularly by a child, unused part-tablets should be returned to the open blister space and inserted back into the carton.
In case of accidental oral ingestion, seek medical advice immediately and show the label or the package leaflet to the physician.
Pregnant women should take special care to avoid accidental oral exposure because angiotensin converting enzyme (ACE) inhibitors have been found to affect the unborn child during pregnancy in humans.

Adverse reactions (frequency and seriousness)
In double-blind clinical trials in dogs with congestive heart failure, the product was well tolerated with an incidence of adverse reactions lower than observed in placebo treated dogs.
A small number of dogs may exhibit transient vomiting, incoordination or signs of fatigue.
In cats and dogs with chronic kidney disease, the product may increase plasma creatinine concentrations at the start of therapy. A moderate increase in plasma creatinine concentrations following administration of ACE inhibitors is compatible with the reduction in glomerular hypertension induced by these agents, and is therefore not necessarily a reason to stop therapy in the absence of other signs.
The product may increase food consumption and body weight in cats.
Emesis, anorexia, dehydration, lethargy and diarrhoea have been reported in rare occasions in cats.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

Use during pregnancy, lactation or lay
Do not use during pregnancy or lactation. The safety of the product has not been established in breeding, pregnant or lactating dogs and cats. Benazepril reduced ovary/oviduct weights in cats when administered daily at 10 mg/kg body weight for 52 weeks. Embryotoxic effects (foetal urinary tract malformation) were seen in trials with laboratory animals (rats) at maternally non-toxic doses.
Interaction with other medicinal products and other forms of interaction
In dogs with congestive heart failure, the product has been given in combination with digoxin, diuretics, pimobendan and anti-arrhythmic veterinary medicinal products without demonstrable adverse interactions.
In humans, the combination of ACE inhibitors and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) can lead to reduced anti-hypertensive efficacy or impaired renal function. The combination of the product and other anti-hypertensive agents (e.g. calcium channel blockers, β-blockers or diuretics), anaesthetics or sedatives may lead to additive hypotensive effects. Therefore, concurrent use of NSAIDs or other medications with a hypotensive effect should be considered with care. Renal function and signs of hypotension (lethargy, weakness etc) should be monitored closely and treated as necessary.
Interactions with potassium preserving diuretics like spironolactone, triamterene or amiloride cannot be ruled out. It is recommended to monitor plasma potassium levels when using the product in combination with a potassium sparing diuretic because of the risk of hyperkalaemia.

Amounts to be administered and administration route
Oral use
The product should be given orally once daily, with or without food. The duration of treatment is unlimited.
Dogs:
The product should be administered orally at a minimum dose of 0.25 mg (range 0.25-0.5) benazepril hydrochloride/kg body weight once daily.
The dose may be doubled, still administered once daily, to a minimum dose of 0.5mg/kg (range 0.5-1.0), if judged clinically necessary and advised by the veterinary surgeon.
Cats:
The product should be administered orally at a minimum dose of 0.5 mg (range 0.5-1.0) benazepril hydrochloride/kg body weight once daily.

Overdose (symptoms, emergency procedures, antidotes), if necessary
The product reduced erythrocyte counts in normal cats when dosed at 10 mg/kg body weight once daily for 12 months and in normal dogs when dosed at 150 mg/kg body weight once daily for 12 months, but this effect was not observed at the recommended dose during clinical trials in cats or dogs.
Transient reversible hypotension may occur in cases of accidental overdose. Therapy should consist of intravenous infusion of warm isotonic saline.

Withdrawal period
Not applicable.